Teleflex (NYSE:TFX) shares surged 9.74% in pre-market trading on Thursday following the release of its impressive second-quarter 2025 financial results and an upward revision of its full-year outlook. The medical technology company significantly outperformed analyst expectations, demonstrating robust growth and improved profitability.

For the second quarter, Teleflex reported adjusted earnings per share of $3.73, handily beating the analyst consensus estimate of $3.36 by 11.04%. This represents a 9.06% increase from the $3.42 per share earned in the same period last year. Revenue for the quarter came in at $780.889 million, surpassing the analyst estimate of $771.477 million by 1.22% and marking a 4.16% year-over-year growth.

Buoyed by its strong performance, Teleflex raised its full-year 2025 guidance. The company now projects revenue growth of 9-10% for the year, up from its previous forecast. Additionally, Teleflex increased its outlook for full-year adjusted earnings per share from continuing operations to a range of $13.90-$14.30. This positive revision in the company's financial outlook, coupled with its better-than-expected quarterly results, appears to be the primary driver behind the significant pre-market stock price surge.